daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Innovent Biologics(1801 HK)– More than Just a GLP-1 Play

Novo Nordisk: Is the FDA Approval of Wegovy Worth an Extra $460 Bn?

Understanding Drug Imbursement Price Cuts in China

Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

Independent Insight Provider

Equity Bottom-Up

<ul>
<li>GLP-1s are “a solution” for obesity and not “the solution”. There are over 100 GLP-1s in development and this space could become very commoditised.</li>
<li>Its valuation has certainly become a lot more palatable, and Novo Nordisk is now trading on a FPE of 24.</li>
<li>Lilly’s Zepbound is the preferred GLP-1: Given the better tolerance, and superior results, Zepbound is chosen over Wegovy.</li>
</ul>


GLP-1s are “a solution” for obesity and not “the solution”. There are over 100 GLP-1s in development and this space could become very commoditised.
Its valuation has certainly become a lot more palatable, and Novo Nordisk is now trading on a FPE of 24.
Lilly’s Zepbound is the preferred GLP-1: Given the better tolerance, and superior results, Zepbound is chosen over Wegovy.


Is It Time to Go Long Novo Nordisk (NVO US)?